CoChat

A field guide for cancer diagnostics using cell‐free DNA: From principles to practice and clinical applications

Volckmar, Anna‐Lena, Sültmann, Holger, Riediger, Anja, Fioretos, Thoas, Schirmacher, Peter, Endris, Volker, Stenzinger, Albrecht, Dietz, Steffen · 2018 · Genes, Chromosomes and Cancer
Cited by 207

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Recently, many genome‐wide profiling studies provided insights into the molecular make‐up of major cancer types. The deeper understanding of these genetic alterations and their functional consequences led to the discovery of novel therapeutic opportunities improving clinical management of cancer patients. While tissue‐based molecular patient stratification is the gold standard for precision medicine, it has certain limitations: Tissue biopsies are invasive sampling procedures carrying the risk of complications and may not represent the entire tumor due to underlying genetic heterogeneity. In this context, complementary characterization of genetic information in the blood of cancer patients can serve as minimal‐invasive ‘liquid biopsy’. Fragments of circulating cell‐free DNA (cfDNA) are released from tissues of healthy individuals as well as cancer patients. The fraction of cfDNA that is released from primary tumors or metastases (i.e. circulating tumor DNA, ctDNA) represents genetic aberrations in cancer cells, which are a potential source for diagnostic, prognostic, and predictive biomarkers. Recent studies have demonstrated technical feasibility and clinical applications including detection of drug targets and resistance mutations as well as longitudinal monitoring of tumors under therapy. To this end, a variety of pre‐analytical procedures for blood processing, isolation and quantification of cfDNA are being employed and several analytical methods and technologies ranging from PCR‐based single locus assays to genome‐wide approaches are available, which considerably differ in sensitivity, specificity, and throughput. However, broad implementation of ctDNA analysis in daily clinical practice requires a thorough understanding of theoretical, technical, and biological concepts and necessitates standardization and validation of pre‐analytical and analytical procedures across different technologies. Here, we review the pertinent literature and discuss the advantages and limitations of available methodologies and their potential applications in molecular diagnostics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/gcc.22517

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 207

Metadata

Authors
Volckmar, A., Sültmann, H., Riediger, A., Fioretos, T., Schirmacher, P., Endris, V., Stenzinger, A., & Dietz, S.
Venue
Genes, Chromosomes and Cancer
Publisher
Wiley
Published
2017-12-20
Volume
57
Issue
3
Pages
123-139
ISSN
  • 1045-2257 (ISSN-L)
  • 1098-2264
OpenAlex
W2775409355
Cited by
207
References
23
FWCI
6.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A field guide for cancer diagnostics using cell‐free DNA: From principles to practice and clinical applications. https://app.cochat.ai/papers/10.1002/gcc.22517
The paper
Volckmar, A., Sültmann, H., Riediger, A., Fioretos, T., Schirmacher, P., Endris, V., Stenzinger, A., & Dietz, S. (2018). A field guide for cancer diagnostics using cell‐free DNA: From principles to practice and clinical applications. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.22517

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.